37,569 Shares in ARK Genomic Revolution ETF $ARKG Acquired by Trivium Point Advisory LLC

Trivium Point Advisory LLC purchased a new stake in ARK Genomic Revolution ETF (BATS:ARKG) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 37,569 shares of the company’s stock, valued at approximately $1,043,000.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its position in ARK Genomic Revolution ETF by 26.8% during the second quarter. JPMorgan Chase & Co. now owns 4,353,952 shares of the company’s stock worth $106,019,000 after purchasing an additional 920,430 shares during the period. Krilogy Financial LLC acquired a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter worth about $5,806,000. NTV Asset Management LLC acquired a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter worth about $4,449,000. Osaic Holdings Inc. boosted its holdings in shares of ARK Genomic Revolution ETF by 16.0% during the 2nd quarter. Osaic Holdings Inc. now owns 109,353 shares of the company’s stock worth $2,663,000 after buying an additional 15,072 shares during the period. Finally, HighTower Advisors LLC grew its stake in ARK Genomic Revolution ETF by 4.8% in the 3rd quarter. HighTower Advisors LLC now owns 93,991 shares of the company’s stock valued at $2,610,000 after buying an additional 4,288 shares during the last quarter.

ARK Genomic Revolution ETF Price Performance

ARK Genomic Revolution ETF stock opened at $29.98 on Friday. The company’s 50-day moving average price is $30.30 and its two-hundred day moving average price is $29.08. ARK Genomic Revolution ETF has a twelve month low of $17.50 and a twelve month high of $34.39.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.